Abstract: ImmVira, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. Citigroup and CICC are the joint sponsors. In our previous note, we looked at the company's core product MVR-T3011, including its mechanism and clinical data, as well as its management and investor backing. In this note, we look at developments in the company's assets and the competitive setting.
Interested in the full report? Get in touch with our team.